FDA Commissioner Martin Makary on Thursday announced a move away from animal-based drug testing in favor of human-based methods and artificial intelligence to determine drug safety and effectiveness.

Torie Bosch is the First Opinion editor at STAT. First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech ...

The National Institutes of Health announced last week that it will no longer issue funding calls for grant proposals that rely solely on animal testing. Moving forward, all such calls must also ...

The last few weeks have been busy for Jim Corbett. Corbett, the CEO of organ-chip developer Emulate, has been fielding requests from potential clients, as well as from early investors who say they ...

The U.S. Food and Drug Administration announced earlier this month that it will be phasing out animal testing for some new drugs, and instead be using “more effective, human-relevant methods” such as ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...